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Background: UK and European guidelines recommend HIV testing in general practice. We report on the
implementation of the Rapid HIV Assessment trial (RHIVA2) promoting HIV screening in general practice
into routine care.
Methods: Interrupted time-series, difference-in-difference analysis and Pearson-correlation on three
cohorts comprising 42 general practices in City & Hackney (London, UK); covering three periods: pre-
trial (20092010), trial (20102012) and implementation (20122014). Cohorts comprised practices
receiving: “trial intervention” only (n = 19), “implementation intervention” only (n = 13); and neither
(“comparator”) (n = 10). Primary outcomes were HIV testing and diagnosis rates per 1000 people and
CD4 at diagnosis.
Findings: Overall, 55,443 people were tested (including 38,326 among these cohorts), and 101 people
were newly diagnosed HIV positive (including 65 among these cohorts) including 74 (73%) heterosex-
uals and 69 (68%) people of black African/Caribbean background; with mean CD4 count at diagnosis
357 (SD=237). Among implementation intervention practices, testing rate increased by 85% (from
1¢798 (95%CI=(1¢657,1¢938) at baseline to 3¢081 (95%CI=(2¢865,3¢306); p = 0¢0000), diagnosis rate
increased by 34% (from 0¢0026 (95%CI=(0¢0004,0¢0037)) to 0¢0035 (95%CI=(0¢0007,0¢0062); p = 0¢736),
and mean CD4 count at diagnosis increased by 55% (from 273 (SD=372) to 425 (SD=274) cells per mL;
p = 0¢433). Implementation intervention and trial intervention practices achieved similar testing rates
(3¢764 vs. 3¢081; 6% difference; 95% CI=(-5%,18%); p = 0¢358), diagnosis rates (0¢0035 vs. 0¢0081; -13%
difference; 95%CI=(-77%,244%; p = 0¢837), and mean CD4 count (425 (SD=274) vs. 351 (SD=257); 69%
increase; 95% CI=(-61%,249%); p = 0¢359). HIV testing was positively correlated with diagnosis
(r = 0¢114 (95% CI=[0¢074,0¢163])), and diagnosis with CD4 count at diagnosis (r = 0¢011 (95% CI=
[-0¢177,0¢218])).
Interpretation: Implementation of the RHIVA programme promoting nurse-led HIV screening into routine
practice in inner-city practices with high HIV prevalence increased HIV testing, and may be associated with
increased and earlier diagnosis. HIV screening in primary care should be considered a key strategy to reduce
undiagnosed infection particularly among high risk persons not attending sexual health services.Keywords:
HIV testing
Implementation
Interrupted time seriesnovska-griffiths@ucl.ac.uk
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Evidence before this study
We searched PubMed for implementation of a cluster rando-
mised trial, published from Jan 01, 2000, to July 31, 2019, test-
ing the impact of HIV screening of adults in primary care
compared with usual care on rates of HIV testing and diagnosis,
and CD4 count at diagnosis. We found no studies that met these
criteria.
Added value of this study
These findings provide, to our knowledge, evidence that imple-
mentation of nurse-led HIV screening in general practices with
HIV high prevalence into routine care leads to increased HIV
testing, and may be associated with increased and earlier
diagnosis.
Implications of all available evidence
Public health leaders should consider implementing HIV
screening in primary care in high prevalence areas.
Introduction
HIV prevalence continues to rise globally. In the UK, 101,600 peo-
ple were estimated to be living with HIV (PLWH) in 2017. In the
same year, 4,363 people were newly diagnosed with HIV and 1,879
of them (43%) were diagnosed at a late stage of infection, i.e. with
CD4 count below 350 cells permL blood [1]. Early diagnosis and treat-
ment are associated with improved clinical outcomes, reduced trans-
mission, and lower treatment costs [2].
In London, testing interventions have largely reached men who
have sex with men (MSM); however, late diagnosis remains dispro-
portionally high among people who are heterosexual (54% vs. 32% in
MSM), people of black African/Caribbean origin (65%), and those
older than 65 years (63%) [3].
To promote earlier diagnosis, in the UK, more routine HIV testing
is recommended in non-traditional settings including general practi-
ces located in high prevalence areas [4,5]. However, a recent system-
atic review suggested that uptake of HIV testing in primary care
remains low [6]. Furthermore, barriers to HIV testing in primary care
remain across Europe [7], although France and the Netherlands have
reported gradual rises in HIV testing since national recommendations
for GP-led testing were issued [7].
Our group has tested the feasibility, acceptability and the impact
of implementing nurse-led routine HIV testing in general practice
under the Rapid HIV Assessment (RHIVA) umbrella intervention. Our
pilot study in 2009 (RHIVA1) demonstrated that rapid point-of-care
HIV testing offered by a health care assistant at general practice regis-
tration was feasible and acceptable to both patients and staff [8]. Sub-
sequently, using a pragmatic cluster randomised controlled trial
(RHIVA2), we showed that an educational training and support pack-
age promoting nurse-led HIV screening at general practice registra-
tion resulted in increased and earlier diagnosis of HIV [9], and
furthermore, was cost-effective [10].
However, outside of a clinical trial, evidence of the impact of
implementing routine HIV testing in general practice is still lacking.After completing the RHIVA2 trial in September 2012, we offered the
RHIVA intervention to all practices in City and Hackney, two high HIV
prevalence areas in inner London, irrespective of their participation
in the original trial. The local public health authority welcomed the
positive impact of RHIVA on population health and commissioned it
as a clinical service in April 2013. The “RHIVA” intervention is defined
as a routine offer of HIV testing by competency-trained non-medical
staff in general practice, either as part of the RHIVA2 research trial
(the “trial intervention”) or via its post-trial implementation (the
“implementation intervention”); whereas the term implementation
refers to the methods used to support the adoption of RHIVA in the
practices [11].
This paper evaluates the RHIVA implementation across City and
Hackney general practices not previously exposed to the trial inter-
vention, by investigating changes in HIV testing rate, HIV diagnosis
rate, and CD4 count at diagnosis. We aimed to answer the following
three questions: (a) Is there a difference in outcomes between the
RHIVA trial intervention and its post-trial implementation? (b) Is
there a difference in outcomes between the RHIVA implementation
and usual care in comparator practices? (c) What is the association
between HIV testing and diagnosis rates, and between diagnosis rate
and CD4 count at diagnosis, in the presence of RHIVA?
Methods
Setting
The study was conducted in the City of London and the London
borough of Hackney (UK), where the estimated local diagnosed HIV
prevalence rates are 11¢23 and 7¢67 per 1000 per adult population
respectively [3]. All general practices within the borough (44 practi-
ces, September 2012) were invited to implement RHIVA, including
practices that had previously participated in the RHIVA2 trial
(20102012). All adults aged 16 and above registered with a general
practice were included.
Design
We conducted a service evaluation comprising a pragmatic cohort
using an interrupted time series analysis (ITS) to examine the longi-
tudinal impact of the implementation in the borough. HIV testing,
diagnosis and CD4 count at diagnosis data were collected for the
period between April 01, 2009 and December 31, 2014.
Ethics approval
The study utilised secondary anonymised data for which approval
was granted from Camden and Islington NHS Research Ethics Com-
mittee, London and no informed consent from patients was required.
Intervention
Between April 2010 and August 2012, we delivered the RHIVA2
trial intervention across 20 general practices randomised to the inter-
vention arm of the trial (See Fig. 1). This theory-based intervention
[1214] previously described [9,15] includes an initial practice-based
education and training session (tailored to nurses and health care
assistants) to offer nurse-led routine rapid HIV testing at registration,
competency assessment and certification for the completion of
Fig. 1. Consort flow diagram. RHIVA trial and implementation profile.
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nurse, external quality assurance including regular support by the
research team, integration of prompts to offer rapid HIV testing with
the primary care computer template, and incentive payments to the
practices (£10 per rapid test performed and recorded on the tem-
plate). Practices were also able to offer rapid testing in other clinical
encounters, such as contraception or sexual health screening
appointments. This intervention supplemented existing national
antenatal HIV screening and a general practice sexual health local
enhanced service (LES) promoting HIV case detection (incentive pay-
ments of £265 per newly diagnosed patient including referral to the
HIV clinic) introduced in 2006/07 [16].
Forty-five practices were operating at the beginning of the trial,
including 40 practices that took part in the trial and five practices
that declined participation. Of the latter, one practice closed during
the trial period resulting in 44 practices available during implemen-
tation. Forty-two of 44 practices were included in this analysis; two
practices were excluded: one trial intervention practice closed, and
one comparator practice offered walk-in services to homeless people
resulting in disproportionally high testing rates compared to their
small practice list size (see Fig. 1).
Of the 44 practices invited to participate in the implementation,
20 practices had received the intervention during RHIVA2 (trial inter-
vention practices) and 24 had not (20 trial control practices, and 4
non-participating practices) (see Fig. 1). A total of 19 practices were
trained, including 13 de novo trained practices (12 trial control, 1
non-participating practice) and six trial intervention practices forwhom this implementation constituted a reinforcement, i.e. they
received two analogous RHIVA interventions, 28 months apart
[1214]. Since this work focuses on evaluating the impact of the
implementation intervention, in comparison to the trial intervention
or no intervention, we stratified the practices into three cohorts of
interest:
 Trial intervention practices (comprising 19 practices that
received RHIVA during the trial between April 2010 and August
2012).
 Implementation intervention practices (henceforth implementa-
tion practices and comprising 13 de novo trained practices that
received only the implementation intervention between Septem-
ber 2012 and December 2014).
 Implementation comparator practices (henceforth comparator
practices and comprising 10 practices that received no interven-
tion, either during either the trial or the implementation).
Details of the practice cohorts and their characteristics are given
in Tables 1 and 2.
RHIVA implementation
Informed by our previous work [8,9], we modified the interven-
tion prior to implementation as follows: promotion of both rapid or
serology testing in any GP clinical setting (instead of rapid testing at
GP registration only as per trial); discontinuation of regular research
Table 1
a and b: Summary of the descriptive statistics for the baseline cohorts and the people who had an HIV tests across the three practice cohorts.
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assurance through the UK National External Quality Assessment Ser-
vice (https://ukneqas.org.uk/). In parallel, we also conducted an eval-
uation of “missed opportunities” for HIV diagnosis commissioned by
NHS City and Hackney, across 31 practices (11 trial intervention, 15
control) [17]. This evaluation demonstrated evidence of late diagnosis
in general practices preceding the trial. In April 2013, the existing
general practice sexual health service [16] was updated to includeincentive payments between £7 and £10 for any rapid or serology
test performed in addition to the existing payments for case-detec-
tion (£258).
Clinical data
We retrospectively collected anonymised HIV testing data in pri-
mary care, as per the RHIVA2 protocol, using remote searches on the
Table 2
Characteristics of practice cohorts studied during three periods: pre-trial (April 2009 to March 2010), trial (Apr 2010 to Aug 2012), and implementation (September 2012 to December 2014).
Pre-trial period (Apr 2009 Mar 2010)a Trial period (Apr 2010  Aug 2012)a Post-trial implementation period (Sep 2012  Dec 2014)a
Total (April
2009  Dec
2014)a
Cohort
characteristics
Pre-trial
intervention
Trial
intervention
Pre-
implementation
Pre-
comparator
Implementation Comparator
Practice
characteristic
Pre-trial
intervention
(N = 19)
Pre-trial
control
(N = 19)
Pre-trial
non-
participant
(N = 4)
Trial
intervention
(N = 19)
Trial control & trial
non-participant
(N = 13)
Trial control & trial
non-participant
(N = 10)
Trial
intervention +
Implementation
(N = 6)
Trial
intervention,
No
implementation
(N = 13)
Trial control &
Trial non-
participant +
Implementation
(N = 13)
Trial
control &
Trial non-
participant,
No Implementation
(N = 10)
All practices
(N = 42)
Patient characteristic
HIV testing
Patients with
rapid test
0 0 0 4793 0 0 2136 1130 2233 0 10,292
Patients tested
by serologyd
3566 2583 162 10638 4599 2933 4453 6169 5132 4432 45,151
HIV diagnosis
New HIV
diagnoses
9 7 Nil 32 6 8 10 19c 7 3b 101b,c
By rapid testing NA NA NA 11 NA NA 2 5 3 NA 21c
By serology
testing
9 7 Nil 21 6 8 8 14c 4 3b 80b,c
Median CD4
count (IQR)
411 (238
461)
249 (110
354)
NA 259 (168
478)e
117(30374) 302((151383) 411 (206482)f 387 (190541) 459 (192715)g 304 (238439) 318 (186477)
Mean CD4
count (STD)
403 (191) 241 (168) NA 351 (257)e 273(372) 266(152) 378 (197)f 396 (238) 425 (275)g 327 (102) 357 (237)
Black African 7 (78%) 6 (86%) NA 20 (63%) 4 (67%) 6 (75%) 6 (60%) 15 (79%) 4 (57%) 1 (33%) 69 (68%)
Heterosexuals 8 (89%) 5 (71%) NA 23 (72%) 4 (67%) 6 (75%) 7 (70%) 15 (79%) 3 (43%) 3 (67%) 74 (73%)
Male 3 (22%) 2 (29%) NA 19 (59%) 3 (50%) 4 (50%) 7 (70%) 10 (53%) 5 (71%) 1 (33%) 54 (53%)
Mean Age
(range)
38 (1767) 47 (3465) NA 40 (2162) 37 (2149) 38.5 (2653) 38 (2362) 41 (2265) 37 (2154) 39 (3542) 39.5 (1767)
All practice and patient data for these periods are shown. Practice cohorts included in the interrupted time series and difference-in-difference analyses are trial intervention practices including their pre-trial control (highlighted in royal
blue), implementation practices including their pre-implementation control (highlighted in dark blue) and implementation comparator practices and their pre-comparator control (highlighted in light blue).
a Two practices were excluded from this analysis; a trial intervention practice closed down during the implementation period, and a comparator practice offering walk-in services where the number of people tested was higher than the
practice list size.
b As a result of (a) two people newly diagnosed in this comparator practice were excluded from the analysis.
c One potentially newly diagnosed patient from an implementation practice was excluded as we were unable to match their data with Public Health England records.
d Total number of people tested by serology for opportunistic or diagnostic reasons, antenatal screening, or confirmatory testing for rapid testing.
e CD4 count data at diagnosis for four people were not available due to missing data.
f CD4 count data missing due to lack of patient consent.
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Fig. 2. (ac). Smoothed time-series of three outcomes: HIV testing rate (a), HIV diag-
nosis rate (b) and (c) CD4 count at diagnosis over the period April 2009 to December
2014 across 19 trial intervention practices (royal blue line), 13 implementation practi-
ces (dark blue line) and 10 comparator practices (light blue line). The vertical red lines
denote the times of the start of the trial intervention and the implementation respec-
tively. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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computer systems of READ codes used for rapid and serology testing
[9]. A master case report form (CRF), detailing a list of people with a
positive HIV test result confirmed by the local pathology laboratory
(Homerton University Hospital), was generated by the lead HIV clini-
cian (JA) at Homerton Sexual Health Services [9]. CD4 count at the
time of diagnosis were included. Patient data were linked to practi-
ces, and the master CRF was shared with the study team in an anony-
mised fashion, as per the RHIVA2 protocol. In collaboration with
Public Health England (PHE), we externally validated data categoris-
ing people confirmed HIV positive into those with a new HIV diagno-
sis and those previously known to have HIV infection using the
national HIV and AIDS database. The INSTI HIV1/HIV2 Rapid Antibody
Test (bioLytical Laboratories, Canada) finger prick system was used
for rapid testing. Any venous blood sample detected as reactive to
HIV-1or HIV-2 on an Abbott Architect ci8200 analyser (Abbott Diag-
nostics, UK) at Homerton Hospital (London, UK) was sent on to Barts
Health Virology for confirmatory testing with the VIDAS HIV DUO
Quick assay (BioMerieux, UK) and the ImmunoComb II HIV 1 & 2 Bio-
Spot kit assay (Alere, UK). The study has been reported in accordance
with the STARI reporting guidelines for implementation studies [18].
Outcome measures
We constructed time series of the HIV testing data, combining data
from serology and rapid tests, HIV diagnosis and CD4 count associated
to diagnosis separately for each of the three practice cohorts between
April 2009 and December 2014. Using the data, we truncated the
69-month observation period into periods of pre-intervention and
intervention as per Table 1.
We separately considered the pre/during-trial periods for trial
intervention practices, and the pre/during-implementation periods
for implementation and comparator practices respectively, as
described before. To aid visualisation of the temporal trajectory of
testing and diagnosis rates, we smoothed the corresponding time
series of the pooled monthly data for each group using a symmetric
moving average filter with span 5 (testing data) and 8 (diagnosis
data). As illustrated in Figure 2, we defined T0 as the time when data
collection started, T1, T2 as the times when trial intervention started
and ended respectively; and T2, T3 as the times when implementa-
tion started and the last day of data available respectively. Then pre-
intervention periods are defined in Table 1 as TpreðT0;T1Þ for the trial
intervention, and TpreðT1; T2Þ for the implementation and compara-
tor practices respectively; while the intervention periods were Tduring
ðT1; T2Þ for the trial intervention, and TduringðT2;T3Þ for the imple-
mentation and comparator practices. We note that we only had 12
months of pre-trial data, whereas we utilised 28 months of trial, pre-
implementation and implementation data. These data sizes are con-
sidered sufficient for statistical significance testing [19,20].
We used the raw, unsmoothed time series of the data over corre-
sponding Tpre and Tduring periods to calculate the co-primary out-
comes as the monthly HIV testing rate (number of people who
received either rapid or serology HIV testing x 1000/number of regis-
tered patients), monthly HIV diagnosis rate (number of newly diag-
nosed people x 1000/number of registered patients); and CD4 count
at diagnosis for people newly diagnosed with HIV across the three
different practice cohorts. In addition, we calculated the correlation
between rates of HIV testing and HIV diagnosis, and between HIV
diagnosis rate and CD4 count at diagnosis across all practice cohorts.
Statistical analysis
We used mixed effects negative binomial regression models with
random intercepts for GP practices and an offset term for practice
size (number of registered patients) to analyse each outcome sepa-
rately. To estimate the difference in outcomes associated with theintervention period, we fitted a random intercept model with a single
indicator variable for “during-intervention” in each cohort. For the
purpose of comparing the differences associated with the interven-
tion between cohorts, we used indicator variables for “during-inter-
vention” and “cohort” as well as their interaction, so the interaction
term estimated the between-cohort difference in the change over
time. Details of the statistical analysis are presented in Appendix A.
For each analysis we calculated incidence rate ratios (IRRs), and used
bootstrapping with 200 replications to estimate standard errors, 95%
confidence intervals (95% CI), and p-values. Finally, we explored
whether increased HIV testing was associated with increased and
earlier HIV diagnosis by calculating the Pearson correlation coeffi-
cients (r) and the corresponding bootstrapped 95% CI (again using
200 replications) across all practices combined, over the entire 69-
month observation period.
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Baseline characteristics were similar for sex, age, and ethnic origin
across all three practice cohorts (Table 1). Table 1 shows that in
implementation and comparator practices, people aged 50 and above
and people of black African or Caribbean origin were underrepre-
sented among those tested. There was less evidence of such under-
representation in trial intervention practices.
Across all practices and over the entire 68-month study period
(April 2009 to December 2014), 55,443 people had an HIV test, of
which 45,151 had a serology test and 10,292 a rapid test (Table 2).
Some people may have received both. Across our cohorts, 11,964
people were tested in implementation practices (N = 13) (7,365 dur-
ing the implementation period), 18,997 in trial intervention practices
(N = 19, 15,431 during the trial) [9], and 7,365 in comparator practi-
ces (n = 10, 4,432 during implementation) (Tables 1 and 2).
Across all practices, a total of 101 people were newly diagnosed
with HIV, of whom 21 (21%) were diagnosed by rapid testing; 74
(73%) were heterosexual and 69 (68%) were people of black African/
Caribbean background. Among the three cohorts, 65 people were
newly diagnosed, including 13 people (three diagnosed by rapid test-
ing) in implementation practices, 41 (11 diagnoses by rapid testing)
in trial intervention practices, and 11 in comparator practices
(Table 2).
During the implementation period, a total of 26 patients had a
reactive test result recorded on the EMIS template; of which 10 were
confirmed HIV positive (true positive), two were confirmed HIV neg-
ative (false reactive), two patients were known to Homerton Sexual
Health to be HIV positive, and one patient was unobtainable for con-
firmatory testing; the remaining 11 reactive results were entry
errors. Three patients had an indeterminate result recorded; two
were confirmed HIV negative, and one patient was unobtainable for
confirmatory testing.
Overall, mean CD4 count at diagnosis was 357 (SD=237) (Table 1);
in implementation practices the mean CD4 count was 425 (SD=274)
during implementation, 351 (SD=257) in trial intervention practices
during the trial, and 327 (SD=102) in comparator practices during
implementation. Furthermore, 44% of people diagnosed in imple-
mentation practices had a CD4 count of less than 350 cells per mL,
compared to 57% in trial intervention practices, and 71% in compara-
tor practices.
Fig. 2(ac) show the smoothed time-series of HIV testing rates,
HIV diagnosis rates and CD4 count at diagnosis across the three prac-
tice cohorts. Table 3 contains the testing rates, diagnosis rates, and
mean CD4 counts in the pre-implementation and implementation
periods, by cohort. Testing rates rose in all three cohorts, but were
greater in trial intervention and implementation practices than in
comparator practices. Testing rates declined somewhat in trialTable 3
HIV testing and diagnosis rates, and mean CD4 count at diagnosis before and during interven
periods are defined in Table 2.intervention practices after the end of the trial. Diagnosis rates
increased in trial intervention and implementation practices, but
decreased in comparator practices. Mean CD4 count at diagnosis
increased in implementation and comparator practices, but
decreased among trial intervention practices. Confidence intervals
for diagnosis rates and mean CD4 counts are wide, reflecting the rela-
tively small number of diagnoses overall.
Table 4 reports the results from statistical models estimating the
difference between intervention and pre-intervention periods for
each of the three cohorts, and difference-in-difference analyses for
the two comparisons of interest. HIV testing increased more in imple-
mentation practices compared to comparator practices by 55% (95%
CI=(40%, 72%); p<0¢001). Diagnosis rate also increased more in imple-
mentation practices compared to comparator practices by 106% (95%
CI=(40%, 754%); p = 0¢17), as did CD4 count at diagnosis by 35%
(95%CI=(70%, 502%)). Although the direction of the difference was
as hypothesised for all three outcomes, the differences in diagnosis
rates and CD4 counts had very wide confidence intervals that
included zero difference, hence not giving conclusive results on the
direction or approximate size of the difference.
Compared to trial intervention practices, in implementation prac-
tices both testing rates (6%; 95%CI=(5%, 18%)) and CD4 count at
diagnosis (69%, 95%CI=(61%,249%)) increased to a larger extend,
while diagnosis rates increased to a smaller extend (13%; 95%CI=
(77%, 244%)). For all three outcomes, the confidence intervals
included zero difference.
Across the whole dataset, increased HIV testing was associated
with increased diagnosis (r = 0¢114; 95% CI=(0¢074, 0¢163)) (Fig. 3(a)),
while the association between HIV diagnosis and CD4 count at diag-
nosis, although positive, was negligible (r = 0¢011; 95% CI=(0¢177,
0¢218)) (Fig. 3(b)).
Discussion
Our analysis suggests that implementation of an educational pro-
gramme promoting nurse-led HIV screening in inner-city high preva-
lence general practices leads to increased HIV testing, compared to
comparator practices. Change in testing rates among implementation
practices was similar to trial intervention practices, suggesting that
promotion of testing in real life settings can be as effective as under
research conditions.
Increased and earlier diagnosis are key clinical and public health
outcomes. In our data, implementation practices had a higher
increase in diagnostic rates in the implementation period compared
to comparator practices, and patients in these practices were, on
average, diagnosed earlier than in comparator practices. These differ-
ences were not statistically reliable. Because rates of new diagnoses
were generally low, we had low statistical power despite ourtion periods across trial intervention, implementation and comparator practices. These
Table 4
Model-based interrupted time series estimates of the difference in testing rate, diagnosis rate, and CD4 count at diagnosis: incidence rate ratios (IRR) for difference between imple-
mentation and pre-implementation periods, and difference-in-difference analyses comparing cohorts.
8 W. Leber et al. / EClinicalMedicine 19 (2020) 100229relatively long observation periods. Nonetheless, we did show that
increased testing rates are associated with higher diagnosis rates in
our data set overall.
Similar to the RHIVA2 trial, the majority of patients diagnosed
during the implementation were heterosexuals and people of black
African/Caribbean origin. These at-risk groups are less likely to attend
sexual health clinics [21], and might benefit most from testing in gen-
eral practice. Therefore, testing in these settings may be considered
as an important adjunct to achieving the UNAIDS strategy of reducing
new infections and HIV-related death by 2030. This would particu-
larly apply to countries with less efficient HIV services than the UK,
where HIV testing in primary care can be expected to be cost-saving
[10].
Continuous training and support may be required for sustained test-
ing and diagnosis in practices. Unlike trial intervention practices, imple-
mentation practices did not receive any ongoing clinical support and
although their testing rates were similar, diagnosis rates were relatively
low, perhaps reflecting low uptake of testing among people of black
African/Caribbean origin and among those aged 50 and above. This
could indicate a training issue and suggest that regular facilitation to
practices may be needed to reach key populations at risk. Alternatively,
the low diagnosis rates may be due to successes of prevention efforts,
gentrification and changes to governmental immigration policies. Of
note, national strategies such as TasP policy and a PrEP pilot in sexual
health centres were unlikely to have impacted on local HIV infection, as
these were not available before July 2015. Finally, loss of follow up of
patients with a reactive or indeterminate result in implementation (but
not in the trial) suggests that a failsafe, including regular data monitor-
ing and feedback to practices, may be required for delivery of safe care.
Our study hasmany strengths. Firstly, we used a comprehensive lon-
gitudinal data set covering over five years, comprising HIV testing and
diagnosis data, from all practices within a large health system, allowingincorporation of the RHIVA2 trial data set with implementation
data, and enabling data stratification into practice cohorts for sta-
tistical analysis. Secondly, data management was consistent dur-
ing the whole study period and across the care continuum,
including usage of the same primary care computer system, con-
firmation of HIV positive tests by the same hospital, and external
validation of new diagnoses by PHE using the national HIV and
AIDS database. Finally, this research is underpinned by a strong
multi-disciplinary team of academic GPs, HIV specialists, public
health and academic researchers, showing importance of collabo-
ration to drive implementation post-trial.
The main weakness of the implementation period is lack of ran-
domisation, allowing less certainty about causality. Cross-contamina-
tion of comparator practices might have occurred during the pre-
trial, trial, and implementation periods. During implementation, con-
tamination of comparator practices might have occurred through
clustering effects by geographical proximity with intervention practi-
ces and by joint working in general practice commissioning consortia
established in 2012. The temporary initial peak in both testing and
diagnosis observed in comparator practices, might have also resulted
from an audit of “missed opportunities for diagnosis” conducted in
31 practices at that time [17]. During the trial and implementation,
comparator practices might have additionally been contaminated by
the Hawthorne effect (i.e. knowing you are in an HIV testing trial (or
in a comparator group) may cause a change in practice) or by dissem-
ination of the National testing guidelines via the media and the local
health authority at commencement of the trial. Pre-trial, engagement
of the local sexual health department with the practices focussing on
testing at-risk populations could have resulted in increased diagnos-
tic rates observed during this period. Finally, cross-contamination
might have also occurred due to people switching practices, as elec-
tronic HIV testing records (but not diagnosis data that we obtained
Fig. 3. (a-b). Pearson correlation coefficient showing the correlation between data on
(a) testing rate and diagnosis rate, and (b) diagnosis data and CD4 count at diagnosis
over the entire time period (April 2009 to December 2014) and across all practice
cohorts combined. The data from Fig. 2(a-b) are pooled together for this correlation
calculation. The confidence intervals were determined using bootstrapping with 200
replications.
W. Leber et al. / EClinicalMedicine 19 (2020) 100229 9from the local laboratory) would follow people when re-registering
with a new practice.
To our knowledge, this is the first study to demonstrate the
impact of implementing nurse-led HIV screening after a cluster rand-
omised controlled trial into routine primary care.
Our study findings have important implications for people, popu-
lations, and health care systems internationally. Our data suggests
that routine implementation of a trial intervention delivers equiva-
lent improvements on HIV testing and diagnosis rates, and CD4 count
at diagnosis. People, particularly those from at-risk key populations,
are likely to benefit from both increased access to testing in a familiar
primary care setting, linkage to prompt treatment and care for those
testing positive, and increased access to effective prevention strate-
gies including PrEP for those testing negative. For public health,
RHIVA provides an additional tool for reducing undiagnosed HIV in
the community. Given its pragmatic and collaborative nature, the
intervention may facilitate sexual health service development in pri-
mary care, knowledge transfer to practice staff, and safe patient
transfer to the HIV clinic. RHIVA has been included in the ECDC public
health guidance on HIV, hepatitis B and C testing (2018) as an exam-
ple of good clinical practice [22], and key research priorities include:
implementation of RHIVA among other high prevalence areas nation-
ally and internationally, expansion of RHIVA to include multiple
chronic infection screening among migrant communities, and appli-
cation of digital technology to enhance uptake of testing.Declaration of Competing Interest
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